Sebacia, Inc., a privately held, commercial stage dermatology and aesthetics company, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for its lead product, Sebacia Microparticles. This significant achievement is a milestone in the treatment of acne and follows the company’s completion of its pivotal study, which clearly demonstrated clinical efficacy and safety of Sebacia Microparticles, and its 510(k) submission to the FDA in June 2018.
In partnership with Meridian Clinical Research, Corinne Howington, MD, led a clinical study for this product at Low Country Dermatology in Savannah, GA. Meridian congratulates Dr. Howington and her team.
Read the full press release from, titled U.S. FDA Clears Sebacia Microparticles for the Treatment of Mild to Moderate Inflammatory Acne at sebacia.com.